Celentis Senescence Sensors harness the power of OFF-ON fluorescence technology to provide a groundbreaking approach to senescent cell detection. These sensors are designed to specifically target senescent cells, offering researchers a precise and reliable tool for studying aging and age-related diseases.

Our OFF-ON fluorescence sensors remain inactive in non-senescent cells where β-galactosidase activity is minimal. However, in senescent cells with elevated β-galactosidase activity, the sensors undergo a rapid activation process, emitting a strong fluorescent signal. This sustained fluorescence can be easily fixed, allowing for long-term monitoring and analysis.

Our Sulfonic-Cy7Gal probe stands out for its ability to monitor the efficacy of pro-senescent and senolytic treatments in real-time. This innovative probe provides researchers with valuable insights into the dynamics of senescent cell clearance, facilitating the development of more effective anti-aging therapies.

The WOS-Cy7Gal probe breaks new ground in senescent cell detection by enabling simultaneous staining with two or more senescent cell biomarkers. This unique capability ensures unequivocal identification and localization of senescent cells, providing researchers with a comprehensive understanding of their distribution and role in aging and disease.

Our senescence sensors have undergone rigorous validation by leading research groups across Spain, the United Kingdom, France, and Germany. Their efficacy is further solidified by a groundbreaking macrostudy published in February 2024 by LEV Foundation, Beverly Hills. This study demonstrates the remarkable potential of our Nav-Gal pro-drug, a navitoclax conjugate with galactose, for senescent cell ablation. In combination with other therapies, Nav-Gal nearly doubles the lifespan of experimental animals.